Sign In
Buy PRCT
$26.33
-0.430 (-1.61%)
At Close: Jun 03, 2026
PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval
08:00am, Thursday, 28'th May 2026
SAN JOSE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the r
AUA Guidelines Strengthen Recommendation for Aquablation® Therapy
08:00am, Thursday, 14'th May 2026
SAN JOSE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the latest update to the American Urological Association (AUA) Guidelines for the management o
PROCEPT BioRobotics Corporation (PRCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
08:40pm, Tuesday, 12'th May 2026
PROCEPT BioRobotics Corporation (PRCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
PROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & June
04:03pm, Thursday, 30'th Apr 2026
SAN JOSE, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative
PROCEPT BioRobotics Corporation (PRCT) Q1 2026 Earnings Call Transcript
02:01am, Thursday, 30'th Apr 2026
PROCEPT BioRobotics Corporation (PRCT) Q1 2026 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
06:46pm, Wednesday, 29'th Apr 2026
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.45 per share a year ago.
PROCEPT BioRobotics Reports First Quarter 2026 Financial Results
04:03pm, Wednesday, 29'th Apr 2026
SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing t
Chicago Capital Doubles Down on PROCEPT BioRobotics, Adds $27 Million in Stock
11:51am, Friday, 24'th Apr 2026
This surgical robotics firm develops minimally invasive systems for urologic procedures, targeting hospitals and specialty clinics.
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of PROCEPT BioRobotics Corporation (“Procept”
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) investor
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) on behalf of investors
PROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026
04:05pm, Thursday, 09'th Apr 2026
SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing t
Reviewing PROCEPT BioRobotics (NASDAQ:PRCT) & OPKO Health (NASDAQ:OPK)
01:40am, Monday, 06'th Apr 2026
OPKO Health (NASDAQ: OPK - Get Free Report) and PROCEPT BioRobotics (NASDAQ: PRCT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two
PROCEPT BioRobotics Corporation $PRCT Shares Acquired by SG Americas Securities LLC
05:32am, Saturday, 04'th Apr 2026
SG Americas Securities LLC boosted its stake in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) by 142.0% in the undefined quarter, according to the company in its most recent 13F filing with the Secur
PRCT: $50.2M ADJUSTED EBITDA LOSS VS. $35M PROJECTED -- LEVI & KORSINSKY, LLP INVESTIGATES
09:00am, Wednesday, 01'st Apr 2026
Procept BioRobotics reported one set of numbers to investors -- the actual figures told a different story NEW YORK, April 1, 2026 /PRNewswire/ -- Investors in Procept BioRobotics (NASDAQ: PRCT) lost
